Navigation Links
Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstrom's Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
Date:6/20/2013

mphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date six Phase III trials have been initiated with ibrutinib and a total of 31 trials are currently registered on www.clinicaltrials.gov. Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib.

About WM
Slow-growing and rare, with an incidence in the U.S. and Europe of approximately 3-5 cases a year per million people,[3] WM belongs to a family of cancers classified as non-Hodgkin lymphoma (NHL). WM originates from B-cells, a type of white blood cell (lymphocyte) that develops in the bone marrow. Approximately 70 percent of WM cases are diagnosed in those over the age of 65,[4] and the median overall survival is 5-11 years.[5],[6]

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Compa
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
2. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
3. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
4. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
5. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
6. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
10. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
(Date:5/22/2015)... , May 22, 2015 The leading ... $13 billion global cardiac rhythm management device market ... found that Medtronic, St. Jude Medical, Boston Scientific ... of this market segment. The healthcare market research ... , uses 2015 as a base year, providing ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4
(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
(Date:5/23/2015)... A live auction will be held to sell over ... other medical facilities around the United States. Various types ... anesthesia, exam and much more. , The live auction ... starting at 9:00am CDT each day. The equipment is at ... Park, IL 60160. Anyone can participate in the auction ...
(Date:5/22/2015)... The world is at a ... intersecting to create new opportunities for leadership in ... at WesternU's 34th annual Commencement Exercises said Wednesday, ... a former San Francisco mayor and likely 2018 ... graduation ceremony for WesternU's colleges of Allied Health ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board ... system’s Chief Financial Officer (CFO), will be leaving the ... the company CFO since 2011. , The Board of ... health system as CFO. Wesley will oversee the health ... Board of Trustees conducts a formal search for a ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
... , SUNDAY, May 13 (HealthDay News) -- A new type ... people who have lost their vision due to degenerative eye ... research with rats. The system uses tiny solar panel-like ... a specially designed pair of goggles equipped with a miniature ...
... new study has found that, contrary to current thinking, taking ... a person,s risk of developing colorectal cancer. Published early online ... Cancer Society, the study also revealed that even long-term use ... cancer risk. In recent years, researchers have thought that ...
... , THURSDAY, May 10 (HealthDay News) -- An advisory panel ... approval of the weight-loss medication lorcaserin, even though concerns remain ... give the nod to the drug, lorcaserin would become the ... decade. The FDA is not bound to follow the advice ...
... is the leading cause of death among children under 5, ... Johns Hopkins Bloomberg School of Public Health. They examined the ... found that 64 percent were attributable to infectious causes and ... the May issue of the Lancet , suggest a ...
... who are making a big difference in the highly ... two early-stage discovery awards from Grand Challenges Explorations, an ... The global health projects will focus on creating ... for low-cost, in-home diagnoses. The prestigious awards ...
... reduced mobility now have access to specialized exercise equipment ... between the University of Alberta and the Spinal Cord ... functional electrical stimulation (FES) rehabilitation therapy machines are now ... the Faculty of Physical Education and Recreation at the ...
Cached Medicine News:Health News:In Rat Study, Eye Device Shows Promise for Restoring Sight 2Health News:Blood pressure drugs don't protect against colorectal cancer 2Health News:FDA Panel Gives Blessing to New Weight-Loss Drug 2Health News:Pneumonia and preterm birth complications are the leading causes of childhood death 2Health News:2 Grand Challenges Explorations grants for global health 2Health News:Partnership provides inclusive workout 2Health News:Partnership provides inclusive workout 3
... The assay is a direct competitive ... in human serum or plasma. A specific ... it available for antibody binding. Estradiol then ... to fluorescein isothiocyanate (FITC) and alkaline phosphatase ...
... the most potent, naturally secreted estrogen and ... ovary [1]. In the ovary, estradiol is ... a less potent estrogen derived from androstenedione. ... body tissues. In men, small amounts of ...
... troponin I (cTnI) has been useful in ... Emergency Departments (ED) with chest pain. 18-20 ... when blood levels of sensitive and specific ... isoenzyme of creatine kinase (CK-MB), and myoglobin, ...
The second-generation Dade Behring Acute Care Troponin I (cTnI) method is the first FDA cleared high sensitivity cTnI assay with the low-end precision necessary to meet the ESC/ACC guidelines (CV <10...
Medicine Products: